A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 09 Jan 2024
At a glance
- Drugs Pacanalotamab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms AMG420
- Sponsors Amgen
Most Recent Events
- 13 May 2022 Status changed from active, no longer recruiting to completed.
- 23 Sep 2021 Planned End Date changed from 3 Feb 2025 to 29 Jun 2022.
- 23 Sep 2021 Planned primary completion date changed from 5 Feb 2022 to 29 Jun 2022.